Advertisement
Advertisement
U.S. Markets close in 2 hrs 22 mins
Advertisement
Advertisement
Advertisement
Advertisement

Cidara Therapeutics, Inc. (20D.F)

Frankfurt - Frankfurt Delayed Price. Currency in EUR
Add to watchlist
0.4735+0.0180 (+3.95%)
As of 12:34PM CEST. Market open.
Advertisement
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.4555
Open0.4507
Bid0.4509 x 40000
Ask0.4639 x 40000
Day's Range0.4507 - 0.4735
52 Week Range0.4120 - 1.9780
Volume2,000
Avg. Volume345
Market Cap31.576M
Beta (5Y Monthly)1.33
PE Ratio (TTM)N/A
EPS (TTM)-0.8840
Earnings DateFeb 23, 2022 - Feb 28, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est6.04
  • Benzinga

    Read Why HC Wainwright Lowered Price Target On This Small Biotech Stock

    U.S. marketing application filing for Cidara Therapeutics Inc's (NASDAQ: CDTX) rezafungin remains on track for mid-2022, setting up a potential early 2023 approval and launch. Cidara confirmed that the application filing of lead antifungal drug rezafungin as a potential first-line treatment for candidemia and invasive candidiasis remains on track for mid-2022, which HC Wainwright takes to mean as late as August. HC Wainwright lowered the price target to $6 from $7.50, citing the challenging capi

  • Zacks

    Cidara Therapeutics (CDTX) Reports Q1 Loss, Lags Revenue Estimates

    Cidara Therapeutics (CDTX) delivered earnings and revenue surprises of -3.85% and 3.93%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire

    Cidara Therapeutics Provides Corporate Update and Reports First Quarter 2022 Financial Results

    SAN DIEGO, May 11, 2022 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for patients facing serious diseases, today reported financial results for the first quarter ended March 31, 2022 and provided an update on its corporate activities and product pipeline. “We continue to advance our pipeline of Cloudbreak DFC product candidates,” said Jeffrey Stein, Ph.D., president and chief exe

Advertisement
Advertisement